Matrix metalloproteinases as valid clinical targets.

Fingleton B
Curr Pharm Des. 2007 13 (3): 333-46

PMID: 17313364 · DOI:10.2174/138161207779313551

The matrix metalloproteinase family of enzymes has been a pharmaceutical target for over 20 years. In that time, many drugs have been developed but none have successfully passed clinical trials. A significant problem has been development of dose-limiting side-effects that were revealed during long-term clinical trials in diseases such as arthritis and various cancers. There are, however, other clinical settings where evidence for MMP function contributing to the pathophysiology of disease is strong. A number of these settings will be discussed here together with evidence from animal models that MMP inhibition is a valid strategy to be considered. A major advantage with many of these settings is that drug exposure may not have to be long-term and/or systemic thus reducing the possibility that side-effects will stymie MMPI-based therapy.

MeSH Terms (19)

Animals Arthritis Atherosclerosis Drug Design Extracellular Matrix Proteins Eye Diseases Heart Rupture, Post-Infarction Humans Hypertrophy, Left Ventricular Matrix Metalloproteinase Inhibitors Matrix Metalloproteinases Myocardial Infarction Neoplasms Protease Inhibitors Pulmonary Disease, Chronic Obstructive Respiratory Distress Syndrome Skin Diseases Stroke Vascular Diseases

Connections (2)

This publication is referenced by other Labnodes entities: